Merck Animal Health reinforces its commitment to helping protect U.S. livestock from the New World screwworm threat through industrywide collaboration, ongoing education and innovations such as EXZOLT CATTLE-CA1.
RAHWAY, N.J. June 4, 2026 — Merck Animal Health, known as MSD Animal Health outside the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK), today reaffirmed its commitment to supporting the cattle industry’s response to the growing threat of New World screwworm following confirmation of the first case in U.S. cattle. The company underscored the continued need for industrywide collaboration to combat this devastating parasite. As a leader in livestock health, Merck Animal Health has been at the forefront of developing innovative medicines for the prevention and treatment of NWS, facilitating information sharing and dialogue, and providing educational resources for the livestock industry.
Our commitment to collaboration and education
As part of its proactive response, Merck Animal Health recently hosted a New World screwworm symposium in San Antonio. Held April 22-24, the event brought together cattle producers and veterinarians from high-risk regions. Leading researchers, academic experts, government representatives and Merck Animal Health technical team members delivered programming focused on NWS preparedness, risk mitigation and coordinated strategies to help protect U.S. livestock.
“The U.S. cattle industry successfully eradicated New World screwworm in the past, and renewed vigilance and collaboration across the industry are essential to preventing and managing this evolving threat,” said Rick DeLuca, president of Merck Animal Health. “Merck Animal Health is committed to being a partner in that effort by providing innovative solutions to support veterinarian and producer preparedness.”
During the symposium, experts stressed the importance of coordinated, industrywide efforts to curb the spread and minimize risk. Because NWS affects all warm-blooded animals, preparedness and strong collaboration across stakeholders are critical. Key prevention strategies highlighted by industry leaders include:
- Daily observation of livestock and wildlife to detect wounds and potential infestations early
- Prompt reporting of suspected cases to enable rapid response
- A strong veterinarian relationship to support development of an NWS management plan
Our commitment to innovation
In December 2025, Merck Animal Health received conditional approval from the U.S. Food and Drug Administration for EXZOLT® CATTLE-CA1 (fluralaner topical solution), the first novel ectoparasiticide introduced for beef cattle in several decades. EXZOLT CATTLE-CA1 is a pour-on product for the prevention and treatment of infestations caused by New World screwworm larvae (myiasis). The product has been available in the United States since early spring 2026, with distribution focused on southern border states to help ensure access in regions at the highest risk of NWS outbreak.
“Innovation plays a critical role in how we respond to emerging threats like New World screwworm,” said Justin Welsh, executive director of livestock technical services, Merck Animal Health. “EXZOLT CATTLE-CA1 represents an entirely new drug class never before used in U.S. cattle. When paired with strong veterinary partnerships and proactive management, it gives the industry an important new tool to help protect cattle herds.”
Only EXZOLT CATTLE-CA1 brings a new active ingredient and drug class to the cattle industry, with no known resistance. It is the first and only topical product conditionally approved for NWS prevention and treatment and delivers the active ingredient fluralaner systemically against infestations. EXZOLT CATTLE-CA1 is approved for use in beef cattle 2 months of age and older and in replacement dairy heifers younger than 20 months. It is also conditionally approved for the treatment and control of cattle fever tick.
EXZOLT CATTLE-CA1 is available by prescription in 1-liter and 5-liter presentations. For more information about EXZOLT CATTLE-CA1, visit ExzoltCattle-CA1.com.
IMPORTANT SAFETY INFORMATION:
Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-617.
It is a violation of Federal law to use this product other than as directed in the labeling.
Not for use in humans. Keep out of reach of children. Accidental exposure may cause skin and eye irritation. Highly flammable. Keep away from heat, sparks, open flame or other sources of ignition. Use only for the prevention and treatment of infestations caused by New World screwworm (Cochliomyia hominivorax) larvae (myiasis) and treatment and control of cattle fever tick (Rhipicephalus microplus) in beef cattle 2 months of age and older and replacement dairy heifers less than 20 months of age. Not for use in bulls intended for breeding 1 year of age and older, dairy calves, and veal calves. Cattle must not be slaughtered for human consumption within 98 days of treatment. If cattle are continuously exposed to temperatures at or above 60°F after product administration, then cattle may be slaughtered for human consumption 44 days after treatment. Violative residues may result if cattle are exposed to temperatures below 60°F after administration and are slaughtered at 44 days. For complete safety information and product dosing instructions, refer to the product label.
